Article
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
International journal of radiation oncology, biology, physics - 1 Mar 2020
Dunn Lara A, Riaz Nadeem, Fury Matthew G, McBride Sean M, Michel Loren, Lee Nancy Y, Sherman Eric J, Baxi Shrujal S, Haque Sofia S, Katabi Nora, Wong Richard J, Xiao Han, Ho Alan L, Pfister David G
Abstract excerpt
PURPOSE: Activation of the PI3K/mTOR signaling pathway is common in head and neck squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is synergistic and efficacious when combined with cetuximab, a Food and Drug Administration-approved radiosensitizing agent in the treatment of HNSCC. The agent independently has been shown to enhance radiosensitivity. This study evaluates the addition of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.